VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.61 and traded as low as $0.5570. VistaGen Therapeutics shares last traded at $0.5976, with a volume of 551,172 shares traded.

Key Stories Impacting VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Negative Sentiment: Broad solicitor outreach: Several national plaintiff firms (Rosen, Schall, Faruqi, Pomerantz, Holzer, Bronstein, DJS and others) have issued investor notices about a class action covering purchases from April 1, 2024 to December 16, 2025 and the March 16 lead‑plaintiff deadline — increasing headline risk and potential legal exposure. Read More.
• Negative Sentiment: Multiple firms repeating the message: Follow‑up notices from Holzer & Holzer, Bronstein Gewirtz & Grossman, Pomerantz, Faruqi & Faruqi, the DJS Law Group and others amplify the litigation narrative and may prolong media attention and investor uncertainty. Read More.
• Negative Sentiment: Technical weakness: Market commentary notes VTGN has crossed below its 50‑day moving average, a near‑term bearish technical signal that can trigger automated selling and reinforce negative investor sentiment. Read More.

Wall Street Analysts Forecast Growth

VTGN has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Jefferies Financial Group restated a “hold” rating and issued a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, Stifel Nicolaus lowered VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective on the stock. in a report on Wednesday, December 17th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Stock Down 3.7%

The firm has a fifty day moving average of $0.61 and a 200-day moving average of $2.47. The stock has a market capitalization of $24.06 million, a price-to-earnings ratio of -0.32 and a beta of 0.29.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.14 million. As a group, research analysts forecast that VistaGen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics during the 1st quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of VistaGen Therapeutics during the third quarter valued at $39,000. Millennium Management LLC acquired a new position in VistaGen Therapeutics in the 3rd quarter valued at about $73,000. Bank of America Corp DE lifted its holdings in VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after purchasing an additional 19,331 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in VistaGen Therapeutics in the 3rd quarter worth approximately $112,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.